Salt  ||| S:0 E:5 ||| NNP
intake ||| S:5 E:11 ||| NN
,  ||| S:11 E:13 ||| ,
hypertension ||| S:13 E:25 ||| NN
,  ||| S:25 E:27 ||| ,
and  ||| S:27 E:31 ||| CC
osteoporosis  ||| S:31 E:44 ||| VBG
A  ||| S:44 E:46 ||| DT
high  ||| S:46 E:51 ||| JJ
salt  ||| S:51 E:56 ||| NN
intake  ||| S:56 E:63 ||| NN
has  ||| S:63 E:67 ||| VBZ
been  ||| S:67 E:72 ||| VBN
correlated  ||| S:72 E:83 ||| VBN
with  ||| S:83 E:88 ||| IN
several  ||| S:88 E:96 ||| JJ
pathological  ||| S:96 E:109 ||| JJ
conditions  ||| S:109 E:120 ||| NNS
such  ||| S:120 E:125 ||| JJ
as  ||| S:125 E:128 ||| IN
hypertension ||| S:128 E:140 ||| NN
,  ||| S:140 E:142 ||| ,
cardiovascular  ||| S:142 E:157 ||| JJ
disease ||| S:157 E:164 ||| NN
,  ||| S:164 E:166 ||| ,
renal  ||| S:166 E:172 ||| JJ
calcium  ||| S:172 E:180 ||| NN
stones ||| S:180 E:186 ||| NNS
,  ||| S:186 E:188 ||| ,
and  ||| S:188 E:192 ||| CC
osteoporosis ||| S:192 E:204 ||| NN
.  ||| S:204 E:206 ||| .
Some  ||| S:206 E:211 ||| DT
of  ||| S:211 E:214 ||| IN
these  ||| S:214 E:220 ||| DT
diseases  ||| S:220 E:229 ||| NNS
present  ||| S:229 E:237 ||| VBP
a  ||| S:237 E:239 ||| DT
high  ||| S:239 E:244 ||| JJ
prevalence  ||| S:244 E:255 ||| NN
in  ||| S:255 E:258 ||| IN
the  ||| S:258 E:262 ||| DT
elderly  ||| S:262 E:270 ||| JJ
and  ||| S:270 E:274 ||| CC
common  ||| S:274 E:281 ||| JJ
pathogenetic  ||| S:281 E:294 ||| JJ
mechanisms  ||| S:294 E:305 ||| NNS
are  ||| S:305 E:309 ||| VBP
proposed  ||| S:309 E:318 ||| VBN
for  ||| S:318 E:322 ||| IN
some  ||| S:322 E:327 ||| DT
of  ||| S:327 E:330 ||| IN
them ||| S:330 E:334 ||| PRP
.  ||| S:334 E:336 ||| .
A  ||| S:336 E:338 ||| DT
high  ||| S:338 E:343 ||| JJ
salt  ||| S:343 E:348 ||| NN
intake  ||| S:348 E:355 ||| NN
has  ||| S:355 E:359 ||| VBZ
been  ||| S:359 E:364 ||| VBN
associated  ||| S:364 E:375 ||| VBN
with  ||| S:375 E:380 ||| IN
hypertension  ||| S:380 E:393 ||| NN
as  ||| S:393 E:396 ||| IN
well  ||| S:396 E:401 ||| RB
as  ||| S:401 E:404 ||| IN
osteoporosis  ||| S:404 E:417 ||| NN
and  ||| S:417 E:421 ||| CC
one  ||| S:421 E:425 ||| CD
of  ||| S:425 E:428 ||| IN
the  ||| S:428 E:432 ||| DT
proposed  ||| S:432 E:441 ||| JJ
pathogenetic  ||| S:441 E:454 ||| JJ
mechanisms  ||| S:454 E:465 ||| NN
is  ||| S:465 E:468 ||| VBZ
an  ||| S:468 E:471 ||| DT
increased  ||| S:471 E:481 ||| JJ
calcium  ||| S:481 E:489 ||| NN
excretion  ||| S:489 E:499 ||| NN
in  ||| S:499 E:502 ||| IN
urine ||| S:502 E:507 ||| NN
.  ||| S:507 E:509 ||| .
Urinary  ||| S:509 E:517 ||| JJ
calcium  ||| S:517 E:525 ||| NN
loss  ||| S:525 E:530 ||| NN
induces  ||| S:530 E:538 ||| VBZ
a  ||| S:538 E:540 ||| DT
negative  ||| S:540 E:549 ||| JJ
calcium  ||| S:549 E:557 ||| NN
balance  ||| S:557 E:565 ||| NN
that  ||| S:565 E:570 ||| WDT
may  ||| S:570 E:574 ||| MD
predispose  ||| S:574 E:585 ||| VB
hypertensive  ||| S:585 E:598 ||| JJ
subjects  ||| S:598 E:607 ||| NNS
to  ||| S:607 E:610 ||| TO
developing  ||| S:610 E:621 ||| VBG
greater  ||| S:621 E:629 ||| JJR
bone  ||| S:629 E:634 ||| NN
loss ||| S:634 E:638 ||| NN
.  ||| S:638 E:640 ||| .
The  ||| S:640 E:644 ||| DT
gene  ||| S:644 E:649 ||| NN
which  ||| S:649 E:655 ||| WDT
encodes  ||| S:655 E:663 ||| VBZ
for  ||| S:663 E:667 ||| IN
the  ||| S:667 E:671 ||| DT
thiazide-  ||| S:671 E:681 ||| JJ
sensitive  ||| S:681 E:691 ||| JJ
sodium-chloride  ||| S:691 E:707 ||| JJ
cotransporter  ||| S:707 E:721 ||| NNS
( ||| S:721 E:722 ||| -LRB-
NCCT ||| S:722 E:726 ||| NNP
)  ||| S:726 E:728 ||| -RRB-
represents  ||| S:728 E:739 ||| VBZ
a  ||| S:739 E:741 ||| DT
possible  ||| S:741 E:750 ||| JJ
link  ||| S:750 E:755 ||| NN
between  ||| S:755 E:763 ||| IN
hypertension  ||| S:763 E:776 ||| NN
and  ||| S:776 E:780 ||| CC
osteoporosis ||| S:780 E:792 ||| NN
.  ||| S:792 E:794 ||| .
Subjects  ||| S:794 E:803 ||| NNS
heterozygous  ||| S:803 E:816 ||| VBN
for  ||| S:816 E:820 ||| IN
an  ||| S:820 E:823 ||| DT
inactivating  ||| S:823 E:836 ||| JJ
mutation  ||| S:836 E:845 ||| NN
of  ||| S:845 E:848 ||| IN
NCCT  ||| S:848 E:853 ||| NNP
present  ||| S:853 E:861 ||| VB
a  ||| S:861 E:863 ||| DT
positive  ||| S:863 E:872 ||| JJ
effect  ||| S:872 E:879 ||| NN
on  ||| S:879 E:882 ||| IN
bone  ||| S:882 E:887 ||| NN
density  ||| S:887 E:895 ||| VBZ
as  ||| S:895 E:898 ||| RB
shown  ||| S:898 E:904 ||| VBN
by  ||| S:904 E:907 ||| IN
the  ||| S:907 E:911 ||| DT
significantly  ||| S:911 E:925 ||| RB
higher  ||| S:925 E:932 ||| JJR
Z-scores  ||| S:932 E:941 ||| NN
at  ||| S:941 E:944 ||| IN
the  ||| S:944 E:948 ||| DT
lumbar  ||| S:948 E:955 ||| JJ
spine  ||| S:955 E:961 ||| NN
and  ||| S:961 E:965 ||| CC
total  ||| S:965 E:971 ||| JJ
femur ||| S:971 E:976 ||| NN
.  ||| S:976 E:978 ||| .
Recent  ||| S:978 E:985 ||| JJ
clinical  ||| S:985 E:994 ||| JJ
studies  ||| S:994 E:1002 ||| NNS
also  ||| S:1002 E:1007 ||| RB
support  ||| S:1007 E:1015 ||| VB
the  ||| S:1015 E:1019 ||| DT
benefit  ||| S:1019 E:1027 ||| NN
of  ||| S:1027 E:1030 ||| IN
ACE  ||| S:1030 E:1034 ||| NNP
inhibitors  ||| S:1034 E:1045 ||| NN
in  ||| S:1045 E:1048 ||| IN
reducing  ||| S:1048 E:1057 ||| VBG
fracture  ||| S:1057 E:1066 ||| JJ
risk  ||| S:1066 E:1071 ||| NN
or  ||| S:1071 E:1074 ||| CC
improving  ||| S:1074 E:1084 ||| VBG
bone  ||| S:1084 E:1089 ||| NN
metabolism ||| S:1089 E:1099 ||| NN
.  ||| S:1099 E:1101 ||| .
These  ||| S:1101 E:1107 ||| DT
data  ||| S:1107 E:1112 ||| NNS
suggest  ||| S:1112 E:1120 ||| VBP
that  ||| S:1120 E:1125 ||| IN
the  ||| S:1125 E:1129 ||| DT
renin-angiotensin  ||| S:1129 E:1147 ||| JJ
system  ||| S:1147 E:1154 ||| NN
may  ||| S:1154 E:1158 ||| MD
be  ||| S:1158 E:1161 ||| VB
one  ||| S:1161 E:1165 ||| CD
of  ||| S:1165 E:1168 ||| IN
the  ||| S:1168 E:1172 ||| DT
several  ||| S:1172 E:1180 ||| JJ
factors  ||| S:1180 E:1188 ||| NNS
involved  ||| S:1188 E:1197 ||| VBN
in  ||| S:1197 E:1200 ||| IN
bone  ||| S:1200 E:1205 ||| NN
metabolism ||| S:1205 E:1215 ||| NN
.  ||| S:1215 E:1217 ||| .
Hypertension ||| S:1217 E:1229 ||| NNP
,  ||| S:1229 E:1231 ||| ,
together  ||| S:1231 E:1240 ||| RB
with  ||| S:1240 E:1245 ||| IN
stroke ||| S:1245 E:1251 ||| NN
,  ||| S:1251 E:1253 ||| ,
has  ||| S:1253 E:1257 ||| VBZ
been  ||| S:1257 E:1262 ||| VBN
demonstrated  ||| S:1262 E:1275 ||| VBN
to  ||| S:1275 E:1278 ||| TO
be  ||| S:1278 E:1281 ||| VB
a  ||| S:1281 E:1283 ||| DT
risk  ||| S:1283 E:1288 ||| NN
factor  ||| S:1288 E:1295 ||| NN
for  ||| S:1295 E:1299 ||| IN
osteoporosis ||| S:1299 E:1311 ||| NN
.  ||| S:1311 E:1313 ||| .
Although  ||| S:1313 E:1322 ||| IN
the  ||| S:1322 E:1326 ||| DT
risk  ||| S:1326 E:1331 ||| NN
associated  ||| S:1331 E:1342 ||| VBN
with  ||| S:1342 E:1347 ||| IN
hypertension  ||| S:1347 E:1360 ||| NN
was  ||| S:1360 E:1364 ||| VBD
limited  ||| S:1364 E:1372 ||| VBN
in  ||| S:1372 E:1375 ||| IN
terms  ||| S:1375 E:1381 ||| NNS
of  ||| S:1381 E:1384 ||| IN
relative  ||| S:1384 E:1393 ||| JJ
risk ||| S:1393 E:1397 ||| NN
,  ||| S:1397 E:1399 ||| ,
it  ||| S:1399 E:1402 ||| PRP
may  ||| S:1402 E:1406 ||| MD
have  ||| S:1406 E:1411 ||| VB
a  ||| S:1411 E:1413 ||| DT
significant  ||| S:1413 E:1425 ||| JJ
impact  ||| S:1425 E:1432 ||| NN
on  ||| S:1432 E:1435 ||| IN
the  ||| S:1435 E:1439 ||| DT
general  ||| S:1439 E:1447 ||| JJ
population  ||| S:1447 E:1458 ||| NN
owing  ||| S:1458 E:1464 ||| VBG
to  ||| S:1464 E:1467 ||| TO
the  ||| S:1467 E:1471 ||| DT
high  ||| S:1471 E:1476 ||| JJ
prevalence  ||| S:1476 E:1487 ||| NN
of  ||| S:1487 E:1490 ||| IN
hypertension ||| S:1490 E:1502 ||| NN
.  ||| S:1502 E:1504 ||| .
The  ||| S:1504 E:1508 ||| DT
treatment  ||| S:1508 E:1518 ||| NN
of  ||| S:1518 E:1521 ||| IN
hypertension  ||| S:1521 E:1534 ||| NN
may  ||| S:1534 E:1538 ||| MD
thus  ||| S:1538 E:1543 ||| RB
be  ||| S:1543 E:1546 ||| VB
very  ||| S:1546 E:1551 ||| RB
useful  ||| S:1551 E:1558 ||| JJ
in  ||| S:1558 E:1561 ||| IN
also  ||| S:1561 E:1566 ||| RB
giving  ||| S:1566 E:1573 ||| VBG
protection  ||| S:1573 E:1584 ||| NN
against  ||| S:1584 E:1592 ||| IN
fractures ||| S:1592 E:1601 ||| NN
.  ||| S:1601 E:1603 ||| .
